TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8039761
Drug: Erwinia L-asparaginase
Normalized name: Erwinia L-asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erwinia L-asparaginase
Study: 8039761
Drug: E. Coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. Coli L-asparaginase
Study: 24564266
Drug: Fentanyl (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (50 μg/ml) at an infusion rate of 0.1 μg/kg/min with bolus doses of 1 μg/kg and a 5‐min lockout time
Study: 27808555
Drug: Baclofen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30 mg/day)
Study: 26713528
Drug: Low-dose UTI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UTI (8000 U/kg i.v.)
Study: 26713528
Drug: High-dose UTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UTI and Low-dose UTI
Study: 11708572
Drug: paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol 500 mg plus hyoscine N‐butylbromide 10 mg
Study: 12706495
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (INO) at 20 ppm
Study: 23932307
Drug: IUI at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUI at 34‐36 h after hCG injection (group I, n=106)
Study: 23932307
Drug: IUI simultaneously
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUI simultaneously with hCG administration (group II, n=98)
Study: 20736941
Drug: Chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chronic low-dose zinc exposure
Study: 20736941
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ZnCl2
Study: 12848630
Drug: Once-daily: placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg
Study: 1756692
Drug: Iopamidol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (0.8 osmol/kg; mean dosage 154 +/- 78 ml or 2.1 +/- 1.0 ml/kg)
Study: 6200729
Drug: Propranolol (0.0125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.0125 to 0.15 mg/kg)
Study: 28658026
Drug: 250 mL/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL/min
Study: 25436797
Drug: Chemotherapy (Pemetrexed)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Pemetrexed)
Study: 25436797
Drug: Chemotherapy (Docetaxel)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Docetaxel)
Study: 15977092
Drug: Oral rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rofecoxib 50 mg 1 h before surgery plus intraarticular 0.5 % bupivacaine 20 ml postoperatively
Study: 15977092
Drug: Intraarticular 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular 0.5 % bupivacaine 20 ml postoperatively
Study: 15977092
Drug: Saline 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 20 ml intraarticularly after surgery
Study: 12681866
Drug: 28-day cycles
Normalized name: desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28-day cycles (21 active pills and a pill-free week)
Study: 10640841
Drug: Corticosteroid cream
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid cream (clobetasone butyrate 0.05%)
Study: 30315239
Drug: ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib (420 mg daily) + bendamustine and rituximab (BR)
Study: 10921154
Drug: Weinaian capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weinaian capsule (oral administration)
Study: 7038656
Drug: Once-daily metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily metoprolol
Study: 7038656
Drug: Twice-daily metoprolol
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily metoprolol
Study: 20716629
Drug: Post-treatment Ki-67
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment Ki-67 in the third quartile (20%-29%)
Study: 16938752
Drug: Aerosolized rhDNase
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized rhDNase (Pulmozyme) 2(1/2) mg once daily
Study: 16938752
Drug: No rhDNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rhDNase treatment (control group)
Study: 8382419
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral candidate rotavirus vaccines (RIT 4237, RRV‐1, DxRRV, DS1xRRV)
Study: 16702582
Drug: Twice-a-week weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-week weight training for 6 months
Study: 11391583
Drug: Paclitaxel 60
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 60 mg/m2 and estramustine 900 mg/m2 (Cohort II)
Study: 9493121
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 4-16 mg once a day
Study: 9493121
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil in combination with amlodipine or hydrochlorothiazide
Study: 2038782
Drug: Papaverine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (60 mg)
Study: 31513839
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g E. angustifolia whole fruit powder
Study: 25939657
Drug: Daily 81
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily 81 mg aspirin for 14 days before exercise and a single dose of 325 mg aspirin immediately after exertion
Study: 25939657
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin before exertion
Study: 25939657
Drug: Single-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose aspirin after exertion
Study: 18490865
Drug: Carraguard vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carraguard vaginal gel
Study: 15951127
Drug: Two-part treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-part treatment intervention aimed to reduce long-term benzodiazepine use
Study: 9259652
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg aspirin
Study: 3614964
Drug: Buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3 mg in 10 ml glucose solution)
Study: 3614964
Drug: Morphine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (3 mg in 10 ml glucose solution)
Study: 27206212
Drug: Dexmedetomidine (1μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1μg/kg 10min before anesthesia induction, maintain dose 0.4μg/(kg/h))
Study: 19157672
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching agent
Study: 15942709
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabeprazole
Study: 27612149
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate 0.05% gel
Study: 15148065
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/d)
Study: 18690305
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg bid)
Study: 9014745
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan with G-CSF-primed unprocessed whole blood
Study: 6760969
Drug: Five days
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five days of cefuroxime prophylaxis (0.75 gm three times a day, the first dose being given postoperatively)
Study: 9738752
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (control group)
Study: 31322914
Drug: Immunosuppression, anti-arrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression, anti-arrhythmic medications, heart failure medications, device therapy, ablation therapy, heart transplantation
Study: 29330636
Drug: CT-P6 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P6 (6 mg/kg, 90 min intravenous infusion)
Study: 19445704
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with treatment allocations
Study: 15097246
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (20 mg/day for 4 weeks)
Study: 9652433
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (3.2 x 10(8) cfu)
Study: 9652433
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose (1.6 x 10(5) cfu)
Study: 9652433
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (3.2 x 10(6) cfu)
Study: 9652433
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (1.6 x 10(8) cfu)
Study: 8205868
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose regimen C: 1,000 micrograms at bedtime
Study: 936954
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cephalothin at the induction of anesthesia and another 2 g, 5 and 10 hours after the primary infusion (treatment group)
Study: 30395961
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate and carboxymethyl cellulose solution (HA‐CMC sol)
Study: 18438228
Drug: Experimental energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental energy patches
Study: 29885904
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg
Study: 8180325
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5,000 U twice a day for at least 6 days)
Study: 3724174
Drug: Nonthyroxine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonthyroxine treatment (control group)
Study: 8860065
Drug: aspecific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspecific treatment
Study: 1632114
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.9% NaCl i.v. (Control)
Study: 22453865
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic drugs (FGAs) - perphenazine and haloperidol
Study: 22453865
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic drugs (SGAs) - olanzapine and clozapine
Study: 15999421
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of hyaluronic acid (HA) 5 times daily for 1 week
Study: 15025555
Drug: Aprepitant (125mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125mg day 1, 80mg once daily on days 2 and 3 or 2-5) plus standard therapy (intravenous ondansetron and oral dexamethasone)
Study: 8080985
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus placebo
Study: 12784346
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus standard therapy
Study: 8166188
Drug: Persistent or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistent or recurrent sialidase 8 weeks after treatment
Study: 25988461
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (tapering 15-day course: 60 mg for 5 days, 40 mg for 5 days, 20 mg for 5 days; total cumulative dose = 600 mg; n=181)
Study: 25988461
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (n=181)
Study: 19466959
Drug: Adapalene 0.1%-BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1%-BPO 2.5% fixed-dose combination gel
Study: 18441854
Drug: BPO 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPO 2.5% monotherapy
Study: 16506874
Drug: No physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No physical therapy (control group)
Study: 23163825
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day
Study: 28840750
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 10 mg by intra-articular injection
Study: 28840750
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) 25 mg by intra-articular injection
Study: 24850106
Drug: Concordant provocation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concordant provocation during interlaminar epidural steroid injection
Study: 24850106
Drug: Discordant provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discordant provocation during interlaminar epidural steroid injection
Study: 24359174
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors (SRIs) - clomipramine and paroxetine
Study: 12131867
Drug: Pidotimod (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (400 mg x 2 daily for 15 days, then 400 mg daily for 20 days)
Study: 9690761
Drug: Pulsed field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed field gel electrophoresis (PFGE) assay
Study: 949899
Drug: Clemastine 1
Normalized name: clemastine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 1 mg b.d. for 3 days
Study: 28556062
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination (Lactobacillus plantarum, Lactobacillus brevis, Pediococcus acidilactici), 2 oral tablets per day for 6 weeks
Study: 28556062
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same tablets without live bacteria), 2 oral tablets per day for 6 weeks
Study: 26846042
Drug: Manual flat-trim
Normalized name: phentermine hydrochloride Oral Capsule [Oby-Trim]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual flat-trim toothbrush (Oral-B Indicator)
Study: 11743058
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (reducing sedentary behavior and increasing physical activity)
Study: 30444283
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to treatment
Study: 8498653
Drug: Perfusion flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion flow rate of 2.4 L.min‐1 x m‐2 (Group I)
Study: 8498653
Drug: Perfusion flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion flow rate of 1.2 L.min‐1 x m‐2 (Group II)
Study: 27551725
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with lopinavir/ritonavir (LPV/r‐MT arm)
Study: 27551725
Drug: Standard antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiretroviral therapy (cART arm)
Study: 17136691
Drug: Furosemide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (60 mg) mixed with fresh frozen plasma (FFP)
Study: 17136691
Drug: Furosemide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (60 mg) mixed with human albumin (HA)
Study: 30810347
Drug: DR/ER-MPH 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR/ER-MPH 100 mg with high-fat meal
Study: 29779020
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (4 g/day for 72 postoperative hours)
Study: 20644331
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day for 6 months
Study: 12362927
Drug: Ivermectin 30
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 30 mg (three times a week)
Study: 12362927
Drug: Ivermectin 60
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 60 mg (three times a week)
Study: 12362927
Drug: Ivermectin 90
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 90 mg (single dose)
Study: 12362927
Drug: Ivermectin 120
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 120 mg (single dose)
Study: 2106735
Drug: multi‐dose blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi‐dose blood cardioplegia (BCP)
Study: 398481
Drug: Cefaclor at
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor at a dose of 20 mg/kg/day
Study: 31549255
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 184/22 mcg or 92/22 mcg
Study: 29714423
Drug: Yijingfang (half
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yijingfang (half dose, bid) for 3 months
Study: 29714423
Drug: Wuziyanzong Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuziyanzong Pills (9 g, bid) + L‐carnitine oral liquid (10 ml, bid) for 3 months
Study: 21052638
Drug: PTH(1‐84) (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1‐84) (100 μg daily, subcutaneous injection)
Study: 19278378
Drug: Traditional analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional analgesics
Study: 16914234
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of pediatric inactivated HA vaccine (Avaxim 80) at 6 months of age (Group B)
Study: 6305546
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg)
Study: 24171880
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg three times a day for three months
Study: 21303633
Drug: Dual nostril
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual nostril administration of 50 U insulin
Study: 21303633
Drug: Single nostril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nostril administration of 50 U insulin
Study: 9764987
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid treatment in primary biliary cirrhosis (9 patients underwent second liver biopsy)
Study: 29378542
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass drug administration (MDA) with praziquantel and albendazole before the peak schistosomiasis transmission season
Study: 19537029
Drug: Minimal invasive
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal invasive neurosurgery (MG group)
Study: 2904898
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic treatment (group B)
Study: 6107932
Drug: Naftidrofuryl (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (40 mg i.m. 3-times for 6 days)
Study: 30075569
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600)
Study: 30075569
Drug: Calcitriol 0.25
Normalized name: CALCITRIOL 0.25MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.25 mcg
Study: 25942016
Drug: Power capacities
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Power capacities (Sargent-jump, broad-jump, medicine-ball-throw)
Study: 23782581
Drug: levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.125% plus fentanyl 4 μg ml‐1 (Group F)
Study: 23782581
Drug: levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.125% (Group L)
Study: 19028835
Drug: Thiopental (GABA(A)
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental (GABA(A) receptor agonist)
Study: 14988822
Drug: Ketamine (NMDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (NMDA receptor antagonist)
Study: 6794081
Drug: Naloxone 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 1.6 mg
Study: 17579942
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg for 2 weeks
Study: 15385381
Drug: Single-injection (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection (Group 1)
Study: 15385381
Drug: Dual-injection (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-injection (Group 2)
Study: 27995731
Drug: Insulin isophane
Normalized name: insulin isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin isophane
Study: 1406395
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (colestipol 5 g or 10 g + simvastatin 20 mg/night then 40 mg/night)
Study: 27332627
Drug: Transdermal Rivastigmine
Normalized name: rivastigmine Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Rivastigmine